A new FDA approval in heme/onc. Does it matter for your patients? Set up OncoPulse once and the approvals in the cancers you treat come to your inbox. Free.
@meducationai.bsky.social
@meducationai.bsky.socialA new FDA approval in heme/onc. Does it matter for your patients? Set up OncoPulse once and the approvals in the cancers you treat come to your inbox. Free.
@meducationai.bsky.social
@meducationai.bsky.socialStarting on the leukemia service Monday and haven't touched AML since residency?
A randomized trial of 27 hem/onc fellowship programs found fellows who added podcasts learned more. Prep on your drive in, by topic, free.
@meducationai.bsky.social
@meducationai.bsky.social
@meducationai.bsky.social#BreastCancer #HemOnc #BoardPrep Practice question of the week. Explore 1,500+ board-style hem/onc questions and AI study tools at Meducation AI. Free 7-day trial: meducationai.com
@societyofhemonc.bsky.socialSpeakers for the 4th SOHO Israel Meeting are announced, including Drs. Courtney DiNardo, Guillermo Garcia-Manero and Gail Roboz. Register at hematology2026.forms-wizard.biz #SOHOIsrael #HemOnc #MedSky
@meducationai.bsky.socialYou can bring AI agents to your tumor board, and it's simpler than you think. Run a de-identified case, then take the literature into the real discussion. Free with OncoPulse.
@hemehub.bsky.social🩸Our case discussion on Smoldering Multiple Myeloma with Shaji Kumar, MD and Adeel Khan, MD is now available to watch on YouTube!
⮕ Watch the full session: youtu.be/vbFJmFe0vjE?...
#SmolderingMyeloma #MultipleMyeloma #Myeloma #Hematology #HemOnc #Oncology #MedicalEducation #MedEd #HemeHub
@meducationai.bsky.social
@meducationai.bsky.socialOfirnoflast final phase 2 at SOHO 2026, in ESA-refractory lower-risk MDS.
30 evaluable patients: 66.7% hematologic improvement, 55.6% became transfusion independent, median 28 weeks. A NEK7 inhibitor, so it targets inflammation.
@meducationai.bsky.social
@societyofhemonc.bsky.socialDeep, durable responses in relapsed/refractory B-ALL: dose-dense mini-CVD plus inotuzumab ozogamicin and blinatumomab shows promising results for a hard-to-treat population.
Read more: sohoinsider.com/news/dose-de...
#HemOnc #Leukemia
@meducationai.bsky.socialFinding the newest podcast episode on the cancer you're studying shouldn't take longer than the episode.
This week we shipped a podcast player sorted by cancer type. Watch what happens when you tap one. Free.
@meducationai.bsky.social#PancreaticCancer #HemOnc #BoardPrep Practice question of the week. Meducation AI has 1,500+ board-style hem/onc questions plus AI study tools for fellows. Free 7-day trial: meducationai.com
@meducationai.bsky.socialFDA withdrew the accelerated approval of adagrasib + cetuximab in KRAS G12C mutated mCRC, effective Sept 1.
KRYSTAL-10: median PFS 7.5 vs 8.1 months, median OS 21.6 vs 21.7. Neither significant.
@meducationai.bsky.socialCHMP backed extending teclistamab to R/R myeloma after at least 1 prior therapy, not 3 (meeting of Sept 14 to 17).
MajesTEC-9: median PFS not reached vs 8.2 months, HR 0.29; OS HR 0.60. A committee opinion, not an EU authorisation yet.
@meducationai.bsky.socialStuck on a patient question in clinic with no one around to ask? Specialist AI agents take your de-identified case and report back from each point of view. Free with OncoPulse.
@meducationai.bsky.socialNEJM, Sept 16: in pediatric high-risk B-ALL, 2 cycles of blinatumomab replaced 2 cycles of chemo after consolidation.
4-yr EFS 83.0% vs 70.3%, HR 0.51, n=709. Treatment-related infection 23.9% vs 69.4%.
@meducationai.bsky.social